Literature DB >> 17035739

Glycopeptide resistance in staphylococci.

K Hiramatsu1, H Hanaki.   

Abstract

Glycopeptide antibiotics have become the last bastion for the treatment of multidrug-resistant Gram-positive hospital pathogens, the two main ones being methicillin-resistant S. aureus and enterococci. However, in addition to the emergence of vancomycin resistance in enterococci, certain staphylococcal strains with low-level resistance to glycopeptides have increasingly been isolated from clinical specimens. This review focuses on mechanisms of resistance, epidemiology, control measures and therapeutic options for these staphylococci.

Entities:  

Year:  1998        PMID： 17035739     DOI： 10.1097/00001432-199812000-00002

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN： 0951-7375            Impact factor:   4.915


  8 in total

1.  "Slow VISA," a novel phenotype of vancomycin resistance, found in vitro in heterogeneous vancomycin-intermediate Staphylococcus aureus strain Mu3.

Authors:  Michie Saito; Yuki Katayama; Tomomi Hishinuma; Akira Iwamoto; Yoshifumi Aiba; Kyoko Kuwahara-Arai; Longzhu Cui; Miki Matsuo; Nanae Aritaka; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2014-05-19       Impact factor: 5.191

2.  Glycopeptide resistance in coagulase-negative staphylococci isolated in blood cultures from patients with hematological malignancies during three decades.

Authors:  E Ahlstrand; K Svensson; L Persson; U Tidefelt; B Söderquist
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-05       Impact factor: 3.267

3.  Mutation of RNA polymerase beta subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3.

Authors:  Miki Matsuo; Tomomi Hishinuma; Yuki Katayama; Longzhu Cui; Maria Kapi; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2011-07-11       Impact factor: 5.191

4.  A mutation of RNA polymerase β' subunit (RpoC) converts heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) into "slow VISA".

Authors:  Miki Matsuo; Tomomi Hishinuma; Yuki Katayama; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2015-05-04       Impact factor: 5.191

5.  Inoculum effects of ceftobiprole, daptomycin, linezolid, and vancomycin with Staphylococcus aureus and Streptococcus pneumoniae at inocula of 10(5) and 10(7) CFU injected into opposite thighs of neutropenic mice.

Authors:  Dong-Gun Lee; Yoichi Murakami; David R Andes; William A Craig
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

6.  Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50.

Authors:  L Cui; H Murakami; K Kuwahara-Arai; H Hanaki; K Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

7.  Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.

Authors:  Pamela A Moise-Broder; Alan Forrest; Mary C Birmingham; Jerome J Schentag
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

8.  Silver resistance in MRSA isolated from wound and nasal sources in humans and animals.

Authors:  Jia V Loh; Steven L Percival; Emma J Woods; Nicola J Williams; Christine A Cochrane
Journal:  Int Wound J       Date:  2009-02       Impact factor: 3.315
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.